

GLAXOSMITHKLINE PLC
Form 6-K
April 04, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending April 2013

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 28 March 2013, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.25 per Ordinary Share, and notional ADSs at a price of \$46.43 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2013 to 31 March 2013:

Non Executive Director	Ordinary Shares	American Depositary Shares (ADSs)
Sir Christopher Gent	2,786.885	
Professor Sir Roy Anderson	594.262	
Dr Stephanie Burns		497.227
Stacey Cartwright	471.311	
Sir Crispin Davis	1,885.246	
Lynn Elsenhans		1,128.489
Judy Lewent		486.418
Sir Deryck Maughan		994.454
Dr Daniel Podolsky		1,134.975
Tom de Swaan	553.279	
Jing Ulrich		313.469
Sir Robert Wilson	594.262	

The Company and the Non-Executive Directors were informed of these allocations on 3 April 2013.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary
4 April 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 04, 2013

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc